Home » Topics » Regulatory » EMA

EMA
RSS

EMA grants accelerated assessment to nintedanib MAA for IPF

June 5, 2014

EMA accepts Hetlioz MAA for review

June 4, 2014

EMA's CHMP confirms negative opinion for RLX-030

May 27, 2014

EMA recommends approval of Nuwiq for children and adults with hemophilia A

May 27, 2014

EMA committee hands down positive opinion on Arzerra for CLL

May 27, 2014

EMA's CHMP recommends approval of Simbrinza to reduce IOP

May 27, 2014

EMA committee makes Halaven recommendation

May 27, 2014

CHMP adopts positive opinion for Plegridy as a treatment for multiple sclerosis

May 27, 2014

EMA committee recommends approval of obinutuzumab

May 26, 2014

CHMP issues positive opinion for Translarna for nonsense mutation DMD

May 26, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...